In December 2018, the AETIONOMY project reached the end of its funded period. The challenge that it faced when they started the project five years ago was more than ambitious. Specifically they set out to create a mechanism-based taxonomy for two neurodegenerative diseases that are known to be idiopathic – which means, that the aetiologies of the diseases are unknown. However, they have come close enough to meeting the goal of the project to share and celebrate its achievements, hence the organization of the final symposium of the AETIONOMY project.
Event objectives
- Presentation of the major achievements of the AETIONOMY consortium.
- Exploring other IMI neurodegenerative disease research projects with an aim to map the AETIONOMY outcomes into the bigger picture of the Innovative Medicines Initative’s (IMI) project portfolio.
- And learning, what other related initiatives in Europe are doing and in a special keynote, how private funding has led to an unparalleled effort in the area of translational neuropsychiatry in the United States.
The final symposium of the AETIONOMY project is aligned with major dissemination events of the IMI AD platform (e.g. the special session organized at AD / PD 2015 in Nice and the IMI “Collaboration in Alzheimer’s disease & beyond: the present and future of the IMI initiatives in neurodegeneration” symposium in Brussels in March 2017).
The sheer amount of excellent work in IMI projects in the area of neurodegenerative diseases makes it impossible to provide each project with a 45 minutes talk; the main achievements of AETIONOMY and the main achievements of IMI neurodegeneration projects are communicated in short presentations of 15 minutes. However, several keynotes and “perspectives” talks were afforded more time and allowed for deeper discussion.
AETIONOMY final symposium
The full video recording and original post of this article are available here on the AETIONOMY website.
Agenda
AETIONOMY final symposium and IMI neurodegeneration initiatives
Hilton Bonn, Berliner Freiheit 2, Bonn, Germany
In the following agenda, you will find for each talk a link refering to
- a photo of the speaker and
- the slide presentation (PDF)
- a recording (MPEG-4) of the presentation.
Day 1 – November 29th
AETIONOMY PRESENTATIONS
Afternoon Session: AETIONOMY and beyond
14:00 | Keynote I: Dementia – big problem; Big Data – big solution? Prof. John Gallacher, University of Oxford, Dementias Platform UK |
Related IMI neurodegeneration initiatives
Day 2 – November 30th, 2018:
Morning Session: Translational Neuroscience – the bigger picture
09:00 | Welcome Coffee |
09:30 | Wrap-up Day 1 Dr. Phil Scordis, UCB Biopharma SPRL and Prof. Dr. Martin Hofmann-Apitius, Fraunhofer Institute SCAI |
09:45 | AETIONOMY crosstalk to the Human Brain Project: Building bridges between major initiatives Prof. Dr. Viktor Jirsa, Director CNRS and Institut de Neurosciences des Systèmes |
10:30 | Interdisciplinarity in Translational Neuroscience – Easier said than done Prof. Dr. Rudi Balling, Luxembourg Centre for Systems Biomedicine |
11:00 | Coffee break |
11:30 | Keynote II: Bridging the Translational Gap: an Integrative Systems Modeling approach for Precision Brain Health Dr. Magali Haas, CEO & President Cohen Veterans Bioscience |
12:30 | Lunch break |
Afternoon Session: Discussion on data sharing and collaborations, and the future of the IMI
13:30 | Panel Discussion: Data sharing and collaboration between IMI neurodegeneration research projects – experiences and suggestions for improvements. Panelists: IMI-project coordinators from industry and academia, Elisabetta Vaudano |
14:30 | Future Directions – after 10 years of IMI Dr. Pierre Meulien, Innovative Medicines Initiative |
15:30 | Summary and Conclusion Dr. Phil Scordis, UCB Biopharma SPRL and Prof. Dr. Martin Hofmann-Apitius, Fraunhofer Institute SCAI |
16:00 | Closure |